Genflow Biosciences awaits key aging trial results in early 2026, while Seeing Machines achieved profitability and received a royalty boost.

Genflow Biosciences is entering a pivotal 2026, with unblinding of its dog aging trial expected in Q1, focusing on biological age via methylation clocks, muscle biopsies, and mitochondrial function. Positive results could trigger a licensing deal and non-dilutive funding. The company is also advancing its MASH pipeline targeting advanced fibrosis and liver cancer prevention. Meanwhile, Seeing Machines received a lump sum royalty payment in January 2026, triggered by a production change, boosting cash flow and profitability. The company achieved cash-flow breakeven by year-end 2025 and recorded its first profitable month, with full-year profitability expected in the second half of 2026. It also showcased advanced driver monitoring tech at CES.